Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a heterogeneous, progressive X-linked recessively inherited lysosomal storage disease that is caused by a deficiency of the enzyme iduronate-2-sulfatase, resulting in abnormal tissue accumulation of the glycosaminoglycans, dermatan sulfate and heparan sulfate. The disorder results from mutations in IDS, which is located at Xq28. Over 300 pathogenic mutations have been identified to date. The management of MPS II requires multidisciplinary care because of the many affected organ systems. Replacement of functional enzyme to involved tissues has been a focus of various therapies for several decades. The transplantation of hematopoietic stem cells provides enzymatic reconstitution in many target tissues, but the clinical response has been disappointing. Recently, enzyme replacement therapy with recombinant human iduronate-2-sulfatase (idursulfase, Elaprase((R)); Shire HGT Pharmaceuticals, Cambridge MA, USA), was approved by the in the US and Europe as a safe and effective treatment for individuals with MPS II. This review presents a comprehensive overview of MPS II and summarizes the recent literature on therapy for the disease.
Burrow
T Andrew
TA
The Division of Human Genetics, Cincinnati Children's Hospital Medical Center, and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Leslie
Nancy D
ND
J Inherit Metab Dis. 2005;28(6):1011-7
16435194
Gastroenterology. 1970 Jun;58(6):856-62
4246486
FEBS J. 2007 Oct;274(19):4944-50
17894779
Acta Paediatr. 2002;91(7):799-804
12200906
J Gene Med. 2003 Jan;5(1):18-29
12516048
Childs Nerv Syst. 1997 Feb;13(2):87-90
9105743
Lancet. 2000 Apr 29;355(9214):1481-5
10801168
J Inherit Metab Dis. 1995;18(1):91-2
7623456
Eur J Pediatr. 2008 Mar;167(3):267-77
18038146
Clin Radiol. 1996 Oct;51(10):719-23
8893643
Bone Marrow Transplant. 2000 May;25(10):1093-7
10828871
Acta Paediatr. 2007 Apr;96(455):71-7
17391447
Acta Paediatr Suppl. 2002;91(439):82-7
12572848
Dev Med Child Neurol. 1983 Aug;25(4):481-9
6413286
Child Care Health Dev. 1981 Jul-Aug;7(4):201-9
6793262
J Med Chem. 2007 Jan 11;50(1):94-100
17201413
Mol Genet Metab. 2007 Mar;90(3):329-37
17185020
Mol Genet Metab. 2007 May;91(1):61-8
17321776
Cell. 2003 May 16;113(4):435-44
12757705
J Inherit Metab Dis. 1995;18(4):413-29
7494400
Arch Dis Child. 1982 Nov;57(11):828-36
6816147
J Med Genet. 1982 Dec;19(6):408-11
6818348
Proc Natl Acad Sci U S A. 1990 Nov;87(21):8531-5
2122463
J Inherit Metab Dis. 2007 Nov;30(6):924-34
17876721
Acta Paediatr Suppl. 2002;91(439):98-9
12572850
Hum Mutat. 1993;2(6):435-42
8111411
Eur J Pediatr. 1998 Jul;157(7):534-8
9686810
J Gene Med. 2005 Nov;7(11):1482-91
15966019
Genet Med. 2006 Aug;8(8):465-73
16912578
Ann Thorac Surg. 2005 Nov;80(5):1911-2
16242483
Hum Genet. 1999 Jul-Aug;105(1-2):151-6
10480370
Pediatr Neurol. 2005 Apr;32(4):270-2
15797184
Transfusion. 1999 Apr;39(4):343-50
10220258
Arch Dis Child. 1998 Sep;79(3):237-41
9875019
J Inherit Metab Dis. 1999 Jun;22(5):638-48
10399096
Mol Genet Metab. 2007 Jun;91(2):183-90
17459751
Am J Hum Genet. 1996 Dec;59(6):1202-9
8940265
Curr Opin Pediatr. 2007 Dec;19(6):628-35
18025928
J Inherit Metab Dis. 2004;27(6):757-66
15505381
J Pediatr. 1996 Jul;129(1):145-8
8757575
Hum Mutat. 2003 Jun;21(6):577-81
12754702
Br J Ophthalmol. 1984 Aug;68(8):590-4
6430340
Hum Mol Genet. 2006 Apr 1;15(7):1225-36
16505002
Clin Genet. 1998 May;53(5):362-8
9660053
Acta Paediatr. 2007 Apr;96(455):63-70
17391446
J Bone Joint Surg Br. 1997 Jul;79(4):576-82
9250742
Trends Genet. 1997 Mar;13(3):121-2
9066272